Key result
Gene disruption or pharmacological inhibition of ClC-3 reduced calcium-activated chloride current and halved vascular smooth muscle cell migration compared to wild-type cells.
ClC-3 plays a critical role in vascular smooth muscle cell migration via regulation of transmembrane Cl(-) flux, suggesting a potential therapeutic target for vascular remodeling diseases.
ClC-3 emerges as candidate target for vascular remodeling; leaves open translation to human efficacy and safety.
Migration of vascular smooth muscle cells (VSMCs) into neointima contributes to atherosclerosis and restenosis. This migration requires coordinated plasmalemmal fluxes of water and ions. Here, we show that aortic VSMC migration depends on the regulation of transmembrane Cl(-) flux by ClC-3, a Cl(-) channel/transporter. The contribution of ClC-3 to plasmalemmal Cl(-) current was studied in VSMCs by electrophysiological recordings. Cl(-) current was negligible in cells perfused with 0 [Ca(2+)]. Raising intracellular [Ca(2+)] to 0.5 μM activated a Cl(-) current (I(Cl.Ca)), approximately half of which was eliminated on inhibition by KN-93 of calmodulin-dependent protein kinase II. I(Cl.Ca) was also halved by inositol-3,4,5,6-tetrakisphosphate, a cellular signal with the biological function of specifically preventing calmodulin-dependent protein kinase II from activating I(Cl.Ca). Gene disruption of ClC-3 reduced I(Cl.Ca) by 50%. Moreover, I(Cl.Ca) in the ClC-3 null VSMCs was not affected by either KN-93 or inositol-3,4,5,6-tetrakisphosphate. We conclude that I(Cl.Ca) is composed of 2 components, one is ClC-3 independent whereas the other is ClC-3 dependent, activated by calmodulin-dependent protein kinase II and inhibited by inositol-3,4,5,6-tetrakisphosphate. We also assayed VSMC migration in transwell assays. Migration was halved in ClC-3 null cells versus wild-type cells. In addition, inhibition of ClC-3 by niflumic acid, KN-93, or inositol-3,4,5,6-tetrakisphosphate each reduced cell migration in wild-type cells but not in ClC-3 null cells. These cell-signaling roles of ClC-3 in VSMC migration suggest new therapeutic approaches to vascular remodeling diseases.
No takes yet. Share an insight, caveat, or question.
Ganapathi et al. (2012) studied Vascular remodeling diseases (atherosclerosis and restenosis). ClC-3 gene disruption or inhibition vs. Wild-type cells was evaluated on Vascular smooth muscle cell migration and plasmalemmal Cl(-) current. Gene disruption or pharmacological inhibition of ClC-3 reduced calcium-activated chloride current and halved vascular smooth muscle cell migration compared to wild-type cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: